Biotechnology & Medical Research

Page 1

Fuse Science Inc engages RBSM LLP as independent registered public accounting firm - Form 8-K

Friday, 30 Jan 2015 04:29pm EST

Fuse Science Inc:On Jan. 26, company notified Kaufman, Rossin & Co., P.A. that it was dismissed as Registrant’s independent registered public accounting firm.On Jan. 26, (Engagement Date), company engaged RBSM LLP as independent registered public accounting firm for company’s fiscal year ended Sept. 30, 2015.

Prosensa Holding BV announces intent to voluntarily delist from NASDAQ

Friday, 30 Jan 2015 08:30am EST

Prosensa Holding BV:Intends to voluntarily delist the registered shares of the company, nominal value 0.01 euros per share, from the NASDAQ Global Select Market (NASDAQ).

Stemline Therapeutics announces SL-701 receives orphan drug designation for the treatment of Glioma

Friday, 30 Jan 2015 08:30am EST

Stemline Therapeutics Inc:Says SL-701 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of glioma.SL-701 is an enhanced immunotherapy designed to activate the immune system to kill malignant gliomas, which are aggressive malignancies of the brain that arise in both adults and children.

Matinas BioPharma establishes Lipid-Based, Anti-Infective Platform, with acquisition of Aquarius BioTechnologies Inc

Friday, 30 Jan 2015 08:25am EST

Matinas BioPharma Holdings Inc:Says it has acquired all of the outstanding stock of Aquarius BioTechnologies Inc.Establishes Lipid-Based, Anti-Infective Platform, with the acquisition.Through the acquisition, company expands its technological portfolio with several product candidates in the field of infectious diseases, which have been supported through the collaboration with and investment by the National Institutes of Health via grants and research contracts.Pursuant to the terms of the Merger Agreement, Matinas is obligated to issue an aggregate of 5,000,000 shares of its common stock at closing, subject to adjustment as set forth in the Merger Agreement.At closing, Matinas BioPharma issued 4,608,020 shares (the "Closing Shares") of its common stock.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.